Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil–lymphocyte ratio and immunohistochemical analyses of the tumour site

Takakura, Kazuki; Ito, Zensho; Suka, Machi; Kanai, Tomoya; Matsumoto, Yoshihiro; Odahara, Shunichi; Miyata, Hiroshi; Haruki, Koichiro; Fujiwara, Yuki; Saito, Ryota; Gocho, Takeshi; Nakashiro, Koh‐ichi; Hamakawa, Hiroyuki; Okamoto, Masato; Kajihara, Mikio; Misawa, Takeyuki; Ohkusa, Toshifumi; Koido, Shigeo

doi:10.3109/00365521.2015.1121515

Cited by 57 publications

(42 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Screening and application of eligibility criteria produced 8 studies and a total of 1519 patients for analysis. [12][13][14][15][16][17][18][19] The characteristics of the included studies are shown in Table 1. Only one study did not find a statistically significant association between a high NLR and OS.…”

Section: Resultsmentioning

confidence: 99%

“…24,25 Half of the included studies failed to comment on the presence of biliary obstruction or instrumentation, whilst the rest simply commented that it was used selectively. 14,[17][18][19] Only half of the studies attempted to control for infection by excluding septic patients and therefore does limit the validity of their results. [14][15][16][17] Across the studies pooled in the meta-analysis, there was a significant amount of heterogeneity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection

Mowbray

Griffith

Hammoda

et al. 2018

HPB

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection

Mowbray

Griffith

Hammoda

et al. 2018

HPB

View full text Add to dashboard Cite

show abstract

“…Therefore, NLR may be a novel marker for survival (23,24). As expected, NLR was also identified as a prognostic factor in patients with PDA following surgical resection.…”

Section: Discussionmentioning

confidence: 99%

“…These reports indicated the potential of CHST15 and CD44 as prognostic factors in patients with PDA following surgical resection. Previous reports have indicated that low neutrophil-to-lymphocyte ratios (NLRs) and low carbohydrate antigen 19–9 (CA19-9) levels may be associated with significantly improved prognoses in patients with PDA (23,24). Thus, the present study analyzed NLRs and CA19-9 levels in the peripheral blood and the expression of CHST15 and CD44 in PDA tissue from surgical specimens as prognostic factors for patients with PDA following surgical resection.…”

Section: Introductionmentioning

confidence: 99%

Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

Patients with pancreatic ductal adenocarcinoma (PDA) typically succumb to mortality early, even following surgical resection. Therefore, prognostic factors associated with early mortality are required to improve the survival of patients with PDA following surgical resection. Carbohydrate sulfotransferase 15 (CHST15) is responsible for the biosynthesis of sulfated chondroitin sulfate E (CS-E), which serves a pivotal function in cancer progression by cleaving CD44. CHST15 and CD44 expression in PDA tissue were assessed as a prognostic factor in patients with PDA following surgical resection. A total of 36 consecutive patients with PDA were enrolled following surgical resection between January 2008 and December 2014. The intensities of CHST15 and CD44 expression were analyzed by immunohistochemical staining. The recurrence period was significantly earlier in the strong CHST15 expression group compared with the negative-to-moderate CHST15 expression group. Overall survival (OS) was also significantly decreased in the strong CHST15 expression group compared with the negative-to-moderate CHST15 expression group. Multivariate analysis also indicated significant associations between CHST15 overexpression and disease-free survival (DFS) and OS. However, expression of CD44 in PDA tissue was not associated with DFS or OS. The present study has demonstrated for the first time that high CHST15 expression in PDA tissue may represent a potential predictive marker of DFS and OS in patients with PDA following surgical resection.

show abstract

“…Both serum sCD163 level and tumoral CD163 expression showed poor prognosis in different types of cancer [17][18][19]. It is necessary to explore whether these two parameters were connected.…”

Section: Correlation Of Serum Scd163 Level With Tumoral Cd163 Expressmentioning

confidence: 99%

Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma

Fei

Pan

et al. 2019

Preprint

View full text Add to dashboard Cite

Background The serum soluble CD163 (sCD163) is elevated in patients with infection disease and several types of cancer. However, the prognostic value of serum sCD163 in pancreatic ductal adenocarcinoma (PDAC) has not yet been investigated. Methods Serum level of sCD163 was measured by using the peripheral blood of 54 patients with PDAC, 20 patients with benign tumor of pancreas, and 30 healthy volunteers (healthy controls). The association between serum sCD163 level and overall survival was analyzed. Receiver operating characteristics (ROCs) curves were generated, and areas under the curve (AUC) were compared to evaluate the diagnostic accuracy, including CA 19-9, CEA, CA 125, CA 153, serum sCD163 level and combination of sCD163 and CA19-9. Results Serum sCD163 level of patients with PDAC was significant higher than patients with benign tumor (p = 0.002) and health controls (p < 0.001). Using ROCs curves, we found that the AUC values of serum sCD163 were higher than those of CA 125 and CA 153, but lower than those of CA 19-9 and CEA. The combination of sCD163 and CA19-9 had higher diagnostic accuracy than CA19-9 or sCD163 alone. In addition, the prognosis of PDAC patients with sCD163 ≥ median was worse than sCD163 < median by using univariate analysis (p = 0.027). Further, multivariate analysis showed that higher level of serum sCD163 was still associated with poorer overall survival (p = 0.030). Serum sCD163 was not associated with tumoral CD163 expression, whereas negatively correlated with lymphocyte to monocyte ratio (r = -0.428, p = 0.001). Conclusion The serum sCD163 has the potential as a new promising parameter to predict the prognosis in PDAC patients.

show abstract

Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil–lymphocyte ratio and immunohistochemical analyses of the tumour site

Abstract: Our results demonstrated the validity of the NLR by IHC analyses and we determined that a higher value of NLR is a trustworthy prognostic factor for patients with PC.

Cited by 57 publications

References 36 publications

A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection

A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection

Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma

Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About